FDA deals a setback to Avedro

In a setback for Avedro, the FDA wants more data before approving its KXL corneal cross-linking technology to treat 2 eye conditions.

Avedro yesterday said the FDA wants more data on its corneal cross-linking technology for treating 2 sight-threatening conditions, meaning the Boston-based medical device company is left with a longer U.S. approval timeline.

Avedro Inc., Food & Drug Administration (FDA)

News Well, Optical/Ophthalmic, Regulatory/Compliance

read more

from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1xDCpJo